AI in Pharma: What a Thai Pharmacy Student Actually Thinks

🚀 Why I'm Paying Attention to This as a Pharmacy Student

I'm a third-year pharmacy student in Thailand. I'm not an AI researcher, I haven't shipped a drug discovery pipeline, and I can't claim to have compressed any timelines. What I have done is spend a lot of time reading about where pharma is heading—and the gap between what's happening globally and what I see around me here is hard to ignore.

AI in pharma isn't hype anymore. Companies like Pfizer and Novartis are using it operationally—not in press releases, in actual workflows. NVIDIA's 2026 GTC demo showed 1.7 million protein folding predictions that would have taken years of wet lab time. That's real. But it's also happening somewhere else, in infrastructure we don't have, with talent pipelines we haven't built.

This post is me trying to figure out what that means for Thailand—and honestly, for what I should be doing with my own next few years.

🔍 What AI Is Actually Doing in Drug Discovery

I want to be honest about what I understand and what I don't, so let me map this out simply.

At the frontier: generative models that design molecules from scratch, protein structure prediction (AlphaFold changed everything here), and AI-assisted clinical trial design that cuts costs and speeds recruitment. These are real capabilities, in production at large pharma.

Closer to everyday reality: supply chain optimization, demand forecasting, manufacturing quality control. Less glamorous, but this is where most mid-tier pharma companies are actually getting value from AI right now.

What I find personally interesting is the middle layer—QSAR and molecular property prediction. Using ML models to predict how a molecule will behave before you synthesize it. This is where computation helps most at the stage before you need a lab. It's not eliminating wet lab work (you still need it for validation), but it dramatically narrows the search space. That's the part I'm trying to learn.

🏗️ Thailand's Position — Honest Assessment

Thailand has real foundations: NSTDA and TCELS as institutional frameworks, a manufacturing base, competitive clinical trial costs, and a geographic position that makes us relevant in SEA healthcare.

But the gaps are real too, and I think they get glossed over in official narratives:

• Talent shortage at the practitioner level. C-suite surveys say executives feel ready for AI. That's not the same as having enough bioinformaticians, data scientists, and computational chemists actually doing the work. University curricula here are still catching up.
• Brain drain. The people who do develop those skills often leave for Singapore, the US, or Europe. The incentive structures haven't been fixed.
• Regulatory lag. Thailand's drug regulatory bodies don't yet have clear frameworks for AI-assisted drug development submissions. Global bodies are still figuring this out too, but we're further behind.
• Dependency risk. Foreign pharma companies invest in Thailand for cost-arbitrage on clinical trials, not to build local capability. That's fine as far as it goes, but without IP protections and knowledge transfer requirements baked into deals, we end up as a service node, not a player.

None of this is unsolvable. But it requires being honest about where we actually are.

🤔 What This Means for Someone Like Me

I'm at a weird intersection. Pharmacy gives me the biological and chemical foundation. I'm learning ML and computational methods on top of that. The field I want to contribute to—computational drug discovery—is exactly where AI is moving fastest.

The honest reality: I'm a beginner. I understand the concepts, I'm learning the tools, but I haven't built anything production-level yet. What I'm trying to figure out is how to build toward something that matters—not just learn techniques in isolation, but develop a view on where the real leverage is.

For Thailand specifically, I think the opportunity isn't in competing with Pfizer's AI infrastructure. It's in building the local substrate—tools, datasets, and methods calibrated to SEA disease patterns and molecular targets that global pharma doesn't prioritize. Tropical diseases, endemic conditions, pharmacogenomics for Asian populations. That's underserved. That's where first-mover advantage is still available.

🌟 The Longer View

Thailand's biotech vision gets accelerated not by chasing the frontier, but by building the unglamorous foundations: data infrastructure, talent pipelines, regulatory clarity, and IP frameworks that actually protect local innovation.

I don't have a roadmap for this at national scale. But at my own scale—figuring out what skills to build, what problems to work on, what to publish—the direction feels clear. Learn the computational side deeply. Find problems where local context gives an edge. Build things that are useful before they're impressive.

That's the version of this I can actually execute.